Ningbo Menovo Pharmaceutical Co (SHSE:603538) Accounts Payable: ¥571 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603538 Ningbo Menovo Pharmaceutical Co Ltd SHSE:603538
74 GF Score
Price ¥27.27
GF Value ¥17.33
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Ningbo Menovo Pharmaceutical Co Accounts Payable?

Ningbo Menovo Pharmaceutical Co SHSE:603538 -4.35% 74 Accounts Payable is ¥571 Mil as of Jun. 2026. GuruFocus rates SHSE:603538 with a GF Score™ of 74/100 and a GF Value™ of ¥17.33 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Ningbo Menovo Pharmaceutical Co's Accounts Payable for the quarter that ended in Jun. 2026 was ¥571 Mil.

Ningbo Menovo Pharmaceutical Co's quarterly Accounts Payable declined from Dec. 2025 (¥512 Mil) to Mar. 2026 (¥460 Mil) but then increased from Mar. 2026 (¥460 Mil) to Jun. 2026 (¥571 Mil).

Ningbo Menovo Pharmaceutical Co's annual Accounts Payable increased from Dec. 2023 (¥554 Mil) to Dec. 2024 (¥634 Mil) but then declined from Dec. 2024 (¥634 Mil) to Dec. 2025 (¥512 Mil).

Ningbo Menovo Pharmaceutical Co Accounts Payable Related Terms

Ningbo Menovo Pharmaceutical Co Accounts Payable Historical Data

* Premium members only.

The historical data trend for Ningbo Menovo Pharmaceutical Co's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ningbo Menovo Pharmaceutical Co Accounts Payable Chart

Ningbo Menovo Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 389.05 499.32 553.70 633.92 511.51

Ningbo Menovo Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 709.39 632.93 511.51 459.68 571.14
SHSE:603538
74GF Score
Ningbo Menovo Pharmaceutical Co Ltd SHSE:603538
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ningbo Menovo Pharmaceutical Co Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of ¥571 Mil mean?
Ningbo Menovo Pharmaceutical Co (SHSE:603538) has a Accounts Payable of ¥571 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Ningbo Menovo Pharmaceutical Co and its competitors.
Is Ningbo Menovo Pharmaceutical Co's Accounts Payable too high?
Ningbo Menovo Pharmaceutical Co's current Accounts Payable is ¥571 Mil. Overall, Ningbo Menovo Pharmaceutical Co has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ningbo Menovo Pharmaceutical Co's Accounts Payable compare to ZTS?
Ningbo Menovo Pharmaceutical Co's Accounts Payable of ¥571 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Ningbo Menovo Pharmaceutical Co and its competitors. Ningbo Menovo Pharmaceutical Co's current Accounts Payable is ¥571 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ningbo Menovo Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Ningbo Menovo Pharmaceutical Co (SHSE:603538) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥17.33, compared to a current price of ¥27.27 — trading 57.4% above its estimated fair value. The current Accounts Payable is ¥571 Mil. Ningbo Menovo Pharmaceutical Co's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Ningbo Menovo Pharmaceutical Co (SHSE:603538), the current Accounts Payable is ¥571 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ningbo Menovo Pharmaceutical Co (SHSE:603538) Overvalued in 2026?

Based on GuruFocus' analysis, Ningbo Menovo Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥27.27 is trading 57.4% above its estimated GF Value™ of ¥17.33. GuruFocus considers Ningbo Menovo Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for SHSE:603538:

  • Accounts Payable: ¥571 Mil
  • GF Value™: ¥17.33 vs. price of ¥27.27 (57.4% above fair value)
  • GF Score™: 74/100 with 4 warning signs

No single metric tells the full story. See the SHSE:603538 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ningbo Menovo Pharmaceutical Co Business Description

Address No.999,Yangfan Road, Room 1406, No.1, High-tech Zone, Ningbo, CHN, 315040
Ningbo Menovo Pharmaceutical Co Ltd is a China-based company is engaged in the research and development, pilot, production and sales of pharmaceutical intermediates, APIs and finished drugs. Its products line includes cardiovascular, central nervous, respiratory, anti-tumor, anti-infective, digestive system, geriatric diseases and anti-viral systems.
74GF Score

Get the complete analysis for SHSE:603538

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥27.27
Price
¥17.33
GF Value